PowerUp Acquisition, Aspire Biopharma enter business combination agreement
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 03 2024
0mins
Merger Agreement: Aspire Biopharma and PowerUp Acquisition Corp. have announced a merger, with plans to form "Aspire Biopharma Holdings, Inc." and list on Nasdaq under the ticker "ASPH," pending regulatory and stockholder approvals.
Product Development: Aspire is focused on innovative drug delivery technologies, including Instaprin, a fast-acting aspirin formulation aimed at improving efficacy and safety in pain management and emergency situations, while also developing various other pharmaceutical applications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
